ABL Diagnostics Releases Next Generation Sequencing Assay and Software for Human Papillomavirus Screening, Genotyping, and Discrimination
ABL Diagnostics, a publicly listed company on Euronext (FR001400AHX6 – ABLD), has announced the release of its latest product, the DeepChek®-HPV Assay. This innovative solution allows for the screening, genotyping, and discrimination of the Human Papillomavirus (HPV) using Next Generation Sequencing (NGS) technology.
The DeepChek®-HPV Assay is designed to be used in conjunction with ABL Diagnostics’ CE-IVD qPCR assay for HPV detection. It can also be integrated with other samples, such as those for HIV or viral hepatitis, in order to increase efficiency and reduce turnaround time and sequencing costs.
The solution also includes a CE-IVD marked downstream analysis software, accessible through both secure Cloud and local installations. This software allows for precise genotyping of the viruses and can discriminate between oncogenic and non-oncogenic strains.
HPV is known to cause genital warts and is a high-risk factor for developing cancer. The global market for HPV testing is projected to reach US$15 billion by 2032, highlighting the importance of ABL Diagnostics’ new product.
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, stated, “Proposing to our customers and partners a robust solution to screen, discriminate, and genotype this virus is an important step for ABL Diagnostics. It is completing our portfolio of microbiology applications and has the potential to become a flagship product together with the GenomeMe technology.”
The ABL Diagnostics team has used their expertise in viral genomics and collaborated with GenomeMe to create a high-quality, efficient, and cost-effective solution for HPV genetic evolution analysis, infectious disease prevention and control, therapeutic regimen development, and product development.
ABL Diagnostics is a worldwide leading international company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products cover a wide range of microbiology applications, with a primary focus on HIV, SARS-CoV-2, tuberculosis, viral hepatitis, and other viral and bacterial targets.
ABL Diagnostics also develops and markets kits for clinical specimen collection and digital solutions, such as Nadis®, an electronic medical record system used in over 200 hospitals in France to manage patients infected by HIV or viral hepatitis.
Ronan Boulme, General Manager of ABL Diagnostics, stated, “The release of the DeepChek®-HPV Assay is a significant milestone for our company. We are proud to offer this innovative solution to healthcare personnel worldwide, providing them with relevant information about high-risk HPV types. Our goal is to contribute to the prevention and control of this virus, as well as to support the development of therapeutic regimens and other products.”
For more information about ABL Diagnostics and their products, please visit their website at www.abldiagnostics.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.